Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost CuttingGBI Research
2/1/2010
107 Pages - ID: XGBR2584307
Countries Covered: China, India
|
Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting
Summary
GBI Research, the leading business intelligence provider, has released its latest report, “Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting.” It provides key data, information and analysis of the major trends and issues affecting the drug discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the model followed by the companies providing such services. The report also provides a detailed analysis of the factors that are driving the drug discovery market, a key segment of the pharmaceutical and healthcare industry, in India and China. The report talks about the key regulations, especially with respect to intellectual property rights protection, and how these regulations have benefited drug discovery companies in these two nations. The study analyses key partnerships between the local companies in the two countries and their western counterparts and the key trends emerging out of such partnerships. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. This research provides a comparative analysis of the two countries and the major differences between India and China when it comes to drug discovery.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes: - Study of major discovery research services including medicinal chemistry, Drug Metabolism and Pharmacokinetics (DMPK), pharmacology and toxicology offered by the Indian and the Chinese drug discovery companies
- Analysis of major therapeutic areas under drug discovery research such as oncology, inflammatory diseases and metabolic diseases
- Study of key Indian and Chinese drug discovery players such as Aurigene, Syngene, WuXi and Shanghai ChemPartner, and their deals/partnerships with western pharma companies
- Analysis of key intellectual property regulations and government support in India and China affecting the drug discovery market
- Analysis of the key drivers that are fueling the growth of the drug discovery market in India and China and future outlook of the drug discovery market in India and China
Reasons to buy
The report will enhance your decision making and will enable you to:- Optimize your discovery research outsourcing through identification of major service capabilities of the Indian and Chinese drug discovery companies
- Develop market entry and market expansion strategies by identifying the key drivers and restraints in the Indian and Chinese drug discovery market
- Identify the key therapeutic areas in which Indian and Chinese drug discovery companies have major capabilities
- Build a strong presence in the Indian and Chinese drug discovery market through identification of key local players for partnerships and their competencies
- Compare both the countries to identify the geography that could provide maximum capability improvement to your discovery research
- Plan better strategies to protect your intellectual property in these countries
- Enhance and frame better marketing strategies through an understanding of the regulatory environment in these countries
Additional InformationDrug Discovery In India and China - Gaining Momentum with Increasing Pressure on Cost Cutting
Description
GBI Research, the leading business intelligence provider, has released its latest report, “Drug Discovery In India and China - Gaining Momentum with Increasing Pressure on Cost Cutting” that provides key data, information and analysis of the major trends and issues affecting the Drug Discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the key services that form a part of drug discovery process. The report also provides a detailed analysis Indian and Chinese drug market in terms of its size, share in the global drug discovery market, major service offering of the companies in India and China along with the major therapeutic areas of focus under those services. The report also talks about the factors that are driving the drug discovery market in India and China. The report delves into the key regulations, especially with respect to intellectual property rights protection in the two countries and how the regulations have benefited the drug discovery companies in these two nations. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. The report also analyses key partnerships between the western pharma and the local companies in the two countries and the key trends emerging out of such partnerships. At the end, the report looks into the major challenges in the future that can restrict the growth of the drug discovery market in India and China.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Rising Financial and Regulatory Pressures on Western Pharma will Continue to Drive the Drug Discovery Research Market Growth in India and China
The pharmaceutical industries in the US and Europe are facing severe financial constraints which are expected to worsen in the years ahead. The pharma companies are under increasing pressure to reduce expenditure due to, the increasing cost of introducing a NME (New Molecular Entities) (more than $3 billion in 2008), tightening FDA regulatory issues, blockbuster drugs worth more than $100 billion set to expire by 2014 and drying pipelines These pressures are expected to drive the companies towards low-cost countries such as India and China to perform their R&D activities, one of their major expenses.
Over the last decade, India and China have developed significant capabilities in drug discovery research along with considerable capabilities in phase I & II clinical trials. Both countries are able to provide significant cost savings in the range of 60-70% for discovery research and clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the Western pharmaceutical industry, outsourcing to low-cost countries is logical.
Inflammatory Diseases, Metabolic Disorders and Oncology are the Three Major Therapeutic Areas of Drug Discovery Research in India and China
While the Indian and Chinese drug discovery companies have developed major service capabilities, many of the companies have also defined their therapeutic research focus. Analysis of 12 Indian and 10 Chinese companies research portfolios reveal that inflammatory diseases (18 companies), metabolic disorders (18) and cancer (16) are the top three therapeutic areas Other major therapy areas include anti-infectives and CNS (Central Nervous System). Major inflammatory disease research includes; COPD (- Chronic Obstructive Pulmonary Disease), RA (Rheumatoid Arthritis), psoriasis, osteoarthritis, ulcerative colitis and atherosclerosis.
Top Five Therapeutic Areas of Focus For Indian and Chinese Drug Discovery Research Companies
Source: GBI Research
However, at the country level the therapeutic focus is found to be different. Indian companies have concentrated their efforts on metabolic disorders; primarily diabetes, obesity and dyslipidemia. Chinese companies have focused on oncology; primarily leukemia, cervical cancer, breast cancer and prostrate cancer.
Deals Landscape is Equally Driven by Mid-Size Pharma and Big Pharma with Oncology and Metabolic Disorders as Key Therapy Area of Focus
With improvements in the capabilities of Indian and Chinese companies, the intensity of discovery research collaborations with Western pharmaceutical companies has increased.. The deals market has been equally driven by big pharma as well as mid-size pharma. Over the past year, 41 major deals have taken place in India and China, of which 20 deals involved mid-size companies while 19 involved big pharma; mainly Merck, AstraZeneca, Johnson & Johnson and Pfizer. Two of the deals were with universities. However, the increasing interest of the mid-size pharmaceutical companies suggests the rising interest of such companies to exploit the cost and quality capabilities of India and China.
Number of Major Discovery Research Deals in India and China by Client Company Type, 2006-2009
Source: GBI Research
Many of these deals were focused on services rather than a therapeutic area. However, among those that had a therapeutic focus; oncology, metabolic disorders, infectious diseases and inflammatory diseases were the major therapies targeted.
Funding Problems and Talent Shortage Will Be the Two Biggest Challenges in Future for the Drug Discovery Players in India and China
While the drug discovery market in India and China is growing rapidly, its future growth faces two major challenges; funding problems, especially for the private companies, and significant talent shortages in biology and chemistry services. While China has considerable government support, a large part of the money goes to government funded research institutions and universities. In India, the government has adopted PPP model as a tool to encourage pharmaceutical innovation but the major beneficiaries include CSIR (Council of Scientific and Industrial Research) affiliated institutes and small pharmaceutical companies. Venture capitalists, in both the countries, are largely risk-averse to invest in early stage R&D activities.
Besides funding problems, the lack of a sufficient talent pool with the specialized skills, experience and employability will create further problems for the drug discovery companies in both the countries.Related Reports:
Pharmaceuticals: Manufacturing, Packaging & Detailing
Pharmaceuticals: Research & Development
Pharmaceuticals: Drug Discovery
|
Currency Conversion by XE.com
|
|
